Evidence map›Paper›PMID 36561318›Full record

ReviewFrontiers in genetics2022

The risk of various types of cardiovascular diseases in mutation positive familial hypercholesterolemia; a review.

Anders Hovland, Liv J Mundal, Marit B Veierød, Kirsten B Holven, Martin Prøven Bogsrud, Grethe S Tell, Trond P Leren, Kjetil Retterstøl

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Methylation status ofEpigenomics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Anders HovlandNordland Heart Center, Bodø, Norway.
Liv J MundalThe Lipid Clinic, Oslo University Hospital, Oslo, Norway.
Marit B VeierødOslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway.
Kirsten B HolvenDepartment of Nutrition, University of Oslo, Oslo, Norway.
Martin Prøven BogsrudUnit for Cardiac and Cardiovascular Genetics, Oslo University Hospital, Oslo, Norway.
Grethe S TellDepartment of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Trond P LerenUnit for Cardiac and Cardiovascular Genetics, Oslo University Hospital, Oslo, Norway.
Kjetil RetterstølThe Lipid Clinic, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOUniversity of Oslo · NONordland Hospital · NOUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial hypercholesterolemia (FH) is a common, inherited disease characterized by high levels of low-density lipoprotein Cholesterol (LDL-C) from birth. Any diseases associated with increased LDL-C levels including atherosclerotic cardiovascular diseases (ASCVDs) would be expected to be overrepresented among FH patients. There are several clinical scoring systems aiming to diagnose FH, however; most individuals who meet the clinical criteria for a FH diagnosis do not have a mutation causing FH. In this review, we aim to summarize the literature on the risk for the various forms of ASCVD in subjects with a proven FH-mutation (FH+). We searched for studies on FH+ and cardiovascular diseases and also included our and other groups published papers on FH + on a wide range of cardiovascular and other diseases of the heart and vessels. FH + patients are at a markedly increased risk of a broad range of ASCVD. Acute myocardial infarction (AMI) is the most common in absolute numbers, but also aortic valve stenosis is by far associated with the highest excess risk. Per thousand patients, we observed 3.6 incident AMI per year compared to 1.9 incident aortic valve stenosis, however, standardized incidence ratio (SIR) for incident AMI was 2.3 compared to 7.9 for incident aortic valve stenosis. Further, occurrence of ischemic stroke seems not to be associated with increased risk in FH+. Clinicians should be aware of the excess risk of almost all kind of ASCVD in FH+, and the neutral risk of stroke need to be studied further in FH + patients.

Indexed as

aortic valve stenosisASCVDcholesterolfamilial hypecholesterolemiaLDLmyocardial infactionstatin (HMG-CoA reductase inhibitor)stroke

Identifiers

PMID36561318
PMCPMC9763610
OpenAlexW4311630806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.